BioMarin Pharmaceutical Inc last reported quarterly results on Oct 6, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.0 billion (+32.0% year over year) and diluted EPS of -$0.63. It usually reports 6–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 6–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 6, 2026
6 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1,025
+32.0%
|
-123
-299.5%
|
-0.63
-293.7%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
990
+19.9%
|
45
-81.4%
|
0.23
-81.3%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
766
+2.8%
|
106
-43.2%
|
0.54
-43.2%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
875
+17.0%
|
-47
-137.3%
|
-0.23
-136.9%
|
|
Oct 7, 2025
7 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
776
+4.1%
|
-31
-129.0%
|
-0.16
-129.1%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
825
+15.9%
|
241
+124.4%
|
1.23
+123.6%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
745
+14.8%
|
186
+109.4%
|
0.95
+106.5%
|
|
Feb 19, 2025
50 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
747
+15.6%
|
125
+513.2%
|
0.63
+465.3%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1048477
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.